EHA 2018 | Investigating melflufen: a peptidase enhanced cytotoxic for myeloma
Paul Richardson
• 14 Jun 2018
The HORIZON study (NCT02963493) aims to determine the efficacy of melflufen in combination with dexamethasone in relapsed/refractory multiple myeloma (MM). In this interview, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the mechanisms of action of this peptidase enhanced cytotoxic and its specificity for MM cells. Dr Richardson also mentions other clinical trials currently investigating melflufen in combination with other drugs, such as the OCEAN study (NCT03151811), and speaks of the benefits of melflufen he hopes will be made clear as a result of these trials. This interview was recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
